How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?

Giuseppe FallaraAlessandro LarcherGiuseppe RosielloDaniele RaggiLaura MarandinoAlberto MartiniGiuseppe BasileGianmarco ColandreaDaniele CignoliFederico BelladelliChiara ReGiacomo MussoFrancesco CeiRoberto BertiniAlberto BrigantiAndrea SaloniaFrancesco MontorsiAndrea NecchiUmberto Capitanio

Published in: World journal of urology (2022)

Patients potentially eligible for adjuvant pembrolizumab have worse characteristics and DFS in the off-trial setting as compared to the placebo arm of the KEYNOTE-564. Patients with either LNI or necrosis were at the highest risk of early-recurrence, which make them the ideal candidate to adjuvant pembrolizumab.

Keyphrases

end stage renal disease
early stage
chronic kidney disease
newly diagnosed
renal cell carcinoma
peritoneal dialysis
clinical trial
study protocol